Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms

Opinion
Video

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

  • Can you provide some background on cGVHD? How does it differ from acute GVHD, and what are the main challenges it presents for patients?
  • From your experience, what are the most common symptoms you see in cGVHD patients, and how do these symptoms impact their daily lives?
Recent Videos
2 KOLs are featured in this series.
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Related Content
FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

Darlene Dobkowski, MA
August 14th 2024
Article

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Chris Ryan
August 11th 2024
Article

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Roman Fabbricatore
July 30th 2024
Article

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

Ashling Wahner
May 7th 2024
Article

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

Darlene Dobkowski, MA
April 26th 2024
Article

A feasibility study on the use of a mobile application for patients after undergoing a stem cell transplant may help care teams quickly identify and treat graft-versus-host disease.

Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment

Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment

Conor Killmurray
February 27th 2024
Article

The antifungal prophylaxis azoles did not impact the safety and efficacy of ruxolitinib in patients with graft-vs-host disease.

© 2024 MJH Life Sciences

All rights reserved.